- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Nectar Lifesciences Limited — Board Meeting, 23-01-2026: Outcome of Board Meeting
23-01-2026 | 04:47 pm
23-01-2026 | 04:47 pm
Nectar Lifesciences' board approved Q3 & 9M results. Consolidated profit was ₹14.27 Cr, affected by discontinued operations. The company completed an ₹81 Cr share buyback and sold its Pharma & Menthol businesses for a combined ₹1,290 Cr.
No comments yet. Be the first to comment!